Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,228 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00524667 | HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia | terminated | Phase 2 | 6 | CancerCare ManitobaOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00797472 | Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease | unknown | Phase 2 | 120 | American Scitech InternationalOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00816959 |
| Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma |
| unknown |
| Phase 3 |
| 1,200 |
| American Scitech InternationalOTHER |
| 1 |
| Jul 20, 2011 |
| clinicaltrials |
| NCT00880867 | Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma | terminated | Phase 1 | 3 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT01125787 | Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab | terminated | Phase 2 | 1 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT01131247 | PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | withdrawn | Phase 2 | 37 | Nevada Cancer InstituteOTHER | 1 | Jul 20, 2011 | clinicaltrials |
| NCT00089037 | Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 15, 2011 | clinicaltrials |
| NCT00413270 | Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 13, 2011 | clinicaltrials |
| NCT00768339 | A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas | terminated | Phase 1 / Phase 2 | 25 | Aegera TherapeuticsINDUSTRY | 2 | Jul 13, 2011 | clinicaltrials |
| NCT00782145 | A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families | completed | Phase 3 | 198 | Tufts Medical CenterOTHER | 1 | Jul 13, 2011 | clinicaltrials |
| NCT01018069 | AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen | terminated | Phase 2 | 60 | Aegera TherapeuticsINDUSTRY | 3 | Jul 13, 2011 | clinicaltrials |
| NCT01378416 | Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 16 | Eisai Inc.INDUSTRY | 1 | Jul 12, 2011 | clinicaltrials |
| NCT00180128 | AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia | unknown | Phase 4 | 80 | Technische Universität DresdenOTHER | 1 | Jul 11, 2011 | clinicaltrials |
| NCT00422890 | Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) | completed | Phase 3 | 10 | Technische Universität DresdenOTHER | 1 | Jul 11, 2011 | clinicaltrials |
| NCT01385891 | Clove In The Treatment Of Relapsed Or Resistant Acute Leukemia In Children(CLOVE) | completed | Phase 2 / Phase 3 | 40 | Istituto Giannina GasliniOTHER | 1 | Jul 8, 2011 | clinicaltrials |
| NCT00466583 | Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 52 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 7, 2011 | clinicaltrials |
| NCT00709813 | Study to Test a Computer-assisted Support System to Improve Patient-centered Care and Symptom Relief in Cancer Patients | completed | N/A | 145 | Oslo University HospitalOTHER | 0 | Jul 6, 2011 | clinicaltrials |
| NCT00112619 | Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors | terminated | Phase 1 | 19 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jun 30, 2011 | clinicaltrials |
| NCT00538876 | Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML | completed | Phase 1 | 30 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 30, 2011 | clinicaltrials |
| NCT00104104 | A Multiple Myeloma Trial in Patients With Bone Metastases | completed | Phase 4 | 179 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00275431 | Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies | completed | Phase 2 | 50 | Ascenta TherapeuticsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00546780 | A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse(BMS TIME-1) | completed | Phase 3 | 31 | Bristol-Myers SquibbINDUSTRY | 2 | Jun 28, 2011 | clinicaltrials |
| NCT00846157 | Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients(NKCell) | unknown | Phase 3 | 276 | NKBio Co.Ltd.INDUSTRY | 1 | Jun 28, 2011 | clinicaltrials |
| NCT00142129 | Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00142155 | Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia | completed | N/A | 300 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00165295 | Sildenafil Citrate in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00004084 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia | completed | Phase 1 / Phase 2 | 21 | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Jun 22, 2011 | clinicaltrials |
| NCT00004107 | Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia | completed | Phase 1 / Phase 2 | 18 | Garden State Cancer Center at the Center for Molecular Medicine and ImmunologyOTHER | 1 | Jun 22, 2011 | clinicaltrials |
| NCT00561743 | A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients | completed | Phase 2 | 50 | Janssen-Ortho Inc., CanadaINDUSTRY | 0 | Jun 21, 2011 | clinicaltrials |
| NCT00283439 | A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | completed | Phase 1 / Phase 2 | 39 | AmgenINDUSTRY | 0 | Jun 20, 2011 | clinicaltrials |
| NCT00926731 | Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) | completed | Phase 1 | 4 | AstraZenecaINDUSTRY | 2 | Jun 16, 2011 | clinicaltrials |
| NCT00891280 | Dose-escalation Study of Oral CX-4945 | unknown | Phase 1 | 55 | Cylene PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
| NCT01199718 | Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 22 | Cylene PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
| NCT01116128 | Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients(D-MP) | terminated | Phase 2 | 8 | Fondazione EMN Italy OnlusOTHER | 1 | Jun 14, 2011 | clinicaltrials |
| NCT00002681 | Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma | completed | Phase 1 / Phase 2 | 25 | Roger Williams Medical CenterOTHER | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00344422 | Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 198 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Jun 10, 2011 | clinicaltrials |
| NCT00474006 | High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML(ADcomparison) | completed | Phase 3 | 398 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00770523 | Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells | completed | — | 52 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 10, 2011 | clinicaltrials |
| NCT01010880 | Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 16 | Biokine Therapeutics LtdINDUSTRY | 1 | Jun 10, 2011 | clinicaltrials |
| NCT01370434 | Two Cycles of PAD Combination by AHCT in MM(PADinMM) | completed | Phase 2 | 43 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00658970 | Evaluation of KX2-391 in Patients With Advanced Malignancies | completed | Phase 1 | 50 | Athenex, Inc.INDUSTRY | 1 | Jun 8, 2011 | clinicaltrials |
| NCT00112775 | BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate | unknown | Phase 2 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 7, 2011 | clinicaltrials |
| NCT00788099 | Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 45 | PharmaMarINDUSTRY | 2 | Jun 7, 2011 | clinicaltrials |
| NCT00398372 | Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment | completed | N/A | 500 | Stanford UniversityOTHER | 1 | Jun 2, 2011 | clinicaltrials |
| NCT00261677 | A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy | completed | Phase 3 | 224 | Ortho Biotech Products, L.P.INDUSTRY | 0 | May 23, 2011 | clinicaltrials |
| NCT00521664 | A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups | completed | Phase 3 | 400 | Technische Universität DresdenOTHER | 1 | May 19, 2011 | clinicaltrials |
| NCT00844441 | Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | N/A | 96 | Fred Hutchinson Cancer CenterOTHER | 2 | May 19, 2011 | clinicaltrials |
| NCT00270049 | Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia | completed | Phase 2 | 195 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00270101 | The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma | completed | Phase 3 | 156 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
Data updated 24 days agoSource updated Jul 20, 2011source: clinicaltrials